Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Rush and UCSF Found Gene Therapy Appeared To Reduce Symptoms of Parkinson’s Disease by 40 Percent

18.10.2006
Michael J. Fox Foundation Awards $1.9 Million for Phase 2 Efficacy Study
Ceregene, Inc., announced today that CERE-120, a gene therapy product in development for the treatment of Parkinson’s disease, was well tolerated and appeared to reduce symptoms by approximately 40% (p

The study was authored by: Dr. Jill Ostrem, UCSF neurologist; Dr. Philip Starr, PhD, and Dr. Paul Larson, who conducted the neurosurgery at UCSF; neurologist Dr. Leo Verhagen, with neurosurgeon Dr. Roy Bakay, at Rush University Medical Center.

The study was supported in part by a grant from The Michael J. Fox Foundation for Parkinson’s Research. Based on the initial results, the Foundation today announced plans to partially fund a Phase 2 study with a $1.9 million grant

“We were encouraged by the results of the Phase 1 trial,” said Deborah W. Brooks, president and CEO of The Michael J. Fox Foundation. “Based on these and on the intriguing efficacy observations, we’re eager to continue to support research in Phase 2 that will more definitively assess the potential of CERE-120 to treat PD.”

CERE-120 is comprised of an adeno-associated virus (AAV) vector carrying the gene for neurturin (NTN), a naturally occurring protein, whose role is to keep dopamine-secreting neurons alive and functioning normally. All 12 patients enrolled in the study underwent stereotactic neurosurgery to deposit CERE-120 into their putamen. The putamen is a region of the brain that undergoes degeneration and reduced dopamine production in Parkinson’s disease patients and this has been closely linked to the major motor deficits in these patients.

All patients entered in the trial were judged to have inadequate control of their disease with standard levadopa therapy and were otherwise potential candidates for additional treatment interventions such as deep brain stimulation (DBS) surgery.

CERE-120 was delivered at 2 different doses, with patients receiving the low dose demonstrating approximately 40% improvement in UPDRS motor “off” scores by 9 months and patients receiving the 4-fold higher dose showing a similar effect 3 months sooner. Patients also demonstrated a 50% reduction in hours of “off” time (i.e., time when normal Parkinson’s medication was ineffective and symptoms were troubling to the patient) and a doubling of good quality “on” time without dyskinesias (i.e., time when a patient is functioning well) according to self-reported diaries.

NTN (neurturin) is a member of the same protein family as glial cell-derived neurotrophic factor (GDNF) and the two molecules have similar pharmacological properties. GDNF has previously been tested in Parkinson's disease patients. Ceregene owns exclusive technology and product rights to CERE-120.

“Targeted delivery of the trophic factor neurturin is a compelling approach to treating Parkinson's disease,” said Dr. Marks. “The safety data and preliminary efficacy data that we have seen in this Phase 1 study are encouraging. Clearly, a larger-scale study is warranted.”

According to Dr. Marks, existing treatments for Parkinson’s disease treat symptoms only, and for only a limited period of time. “Patients with Parkinson’s disease urgently need therapeutic approaches that not only improve symptoms and function, but also have the ability to modify the underlying disease itself in a favorable manner,” he said.

In addition to Dr. Marks, the study was authored by: Dr. Jill Ostrem, UCSF neurologist; Dr. Philip Starr, and Dr. Paul Larson, who conducted the neurosurgery at UCSF; neurologist Dr. Leo Verhagen with neurosurgeon Dr. Roy Bakay, at Rush University Medical Center in Chicago; and Raymond T. Bartus, PhD, who led the clinical and preclinical development of CERE-120 at Ceregene.

“The planned Phase 2 trial will be a randomized controlled trial involving approximately 50 patients, and is designed to test if the efficacy we have seen in our initial Phase 1 trial will hold up in a controlled study,” stated Jeffrey M. Ostrove, PhD, president and CEO of Ceregene.

Eight medical centers will participate in the Phase 2 study: Baylor College of Medicine, Duke University, Orgeon Health Sciences University, University of Alabama at Birmingham, University of Pennsylvania and Mount Sinai College of Medicine. UCSF and Rush will also be participating.

“The Phase 1 data reported today affirms that the functioning of CERE-120 closely resembled its performance in preclinical studies both in terms of its overall safety as well as its possible efficacy,” noted Raymond T. Bartus, PhD, Ceregene’s chief operating officer. “The development of growth factors as a treatment for neurodegenerative diseases has been hampered by the difficulty of delivering them specifically to the targeted areas that need their neuroprotective properties. We believe our programs increasingly demonstrate that gene transfer may represent a safe and effective means of solving this age-old problem,” said Raymond Bartus.

www.rush.edu | EurekAlert!
Further information:
http://www.rush.edu

More articles from Health and Medicine:

nachricht Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Predicting unpredictability: Information theory offers new way to read ice cores

07.12.2016 | Earth Sciences

Sea ice hit record lows in November

07.12.2016 | Earth Sciences

New material could lead to erasable and rewriteable optical chips

07.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>